[go: up one dir, main page]

MXPA00011422A - Derivados de bencimidazol como moduladores de ige. - Google Patents

Derivados de bencimidazol como moduladores de ige.

Info

Publication number
MXPA00011422A
MXPA00011422A MXPA00011422A MXPA00011422A MXPA00011422A MX PA00011422 A MXPA00011422 A MX PA00011422A MX PA00011422 A MXPA00011422 A MX PA00011422A MX PA00011422 A MXPA00011422 A MX PA00011422A MX PA00011422 A MXPA00011422 A MX PA00011422A
Authority
MX
Mexico
Prior art keywords
ige
modulators
benzimidazole derivatives
allergens
allergy
Prior art date
Application number
MXPA00011422A
Other languages
English (en)
Inventor
Jagadish Sircar
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA00011422(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of MXPA00011422A publication Critical patent/MXPA00011422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Amplifiers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

Esta invencion se refiere a una familia de los analogos del diacil bencimidazol, los cuales son inhibidores de la respuesta de IgE a los alergenos. Estos compuestos son utiles en el tratamiento de la alergia y/o el asma o cualesquiera enfermedades en donde la IgE es patogena..
MXPA00011422A 1998-05-22 1999-05-21 Derivados de bencimidazol como moduladores de ige. MXPA00011422A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011322 WO1999061019A1 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE

Publications (1)

Publication Number Publication Date
MXPA00011422A true MXPA00011422A (es) 2002-12-13

Family

ID=22198947

Family Applications (3)

Application Number Title Priority Date Filing Date
MXPA00011422A MXPA00011422A (es) 1998-05-22 1999-05-21 Derivados de bencimidazol como moduladores de ige.
MXPA00011470A MXPA00011470A (es) 1998-05-22 1999-05-21 Analogos de bencimidazol como reguladores de la disminucion de ige.
MXPA00011467A MXPA00011467A (es) 1998-05-22 1999-05-21 Compuestos que tienen propiedades que afectan la ige.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MXPA00011470A MXPA00011470A (es) 1998-05-22 1999-05-21 Analogos de bencimidazol como reguladores de la disminucion de ige.
MXPA00011467A MXPA00011467A (es) 1998-05-22 1999-05-21 Compuestos que tienen propiedades que afectan la ige.

Country Status (22)

Country Link
US (2) US6271390B1 (es)
EP (3) EP1077700B1 (es)
JP (3) JP2002516274A (es)
KR (1) KR100591652B1 (es)
CN (4) CN1317965A (es)
AT (1) ATE292465T1 (es)
AU (3) AU754943B2 (es)
BR (3) BR9910641A (es)
CA (3) CA2332985A1 (es)
CZ (2) CZ20004350A3 (es)
DE (1) DE69924607T2 (es)
ES (1) ES2241285T3 (es)
HU (3) HUP0101894A3 (es)
IL (3) IL139828A0 (es)
MX (3) MXPA00011422A (es)
NO (3) NO20005888L (es)
NZ (2) NZ508416A (es)
PL (3) PL345952A1 (es)
RU (2) RU2236221C2 (es)
UA (2) UA67775C2 (es)
WO (3) WO1999061019A1 (es)
ZA (3) ZA200007754B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
IL139828A0 (en) * 1998-05-22 2002-02-10 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
CA2343101A1 (en) 1998-09-11 2000-03-23 Ajinomoto Co., Inc. Benzene derivatives and medicinal use thereof
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
BR0009322A (pt) * 1999-03-26 2002-04-30 Euro Celtique Sa Pirazóis, imidazóis, oxazóis, tiazóis e pirróis substituìdos com arila e o uso dos mesmos
EP1193255A4 (en) * 1999-07-01 2002-08-07 Ajinomoto Kk HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE
EP1211240A4 (en) 1999-09-01 2003-02-12 Ajinomoto Kk BISCYCLOPROPANOCARBOXYLIC ACID AMIDE COMPOUNDS AND MEDICINAL USE THEREOF
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
ES2291455T3 (es) * 2001-03-12 2008-03-01 Avanir Pharmaceuticals Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
IL159858A0 (en) 2001-07-27 2004-06-20 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
ES2292812T3 (es) 2001-10-19 2008-03-16 Ortho-Mcneil Pharmaceutical, Inc. 2-fenil benzimidazol e imidazo-(4,5)-piridinas como inhibidores de cds1/chk2 y coadyuvantes para quimioterapia o radioterapia en el tratamiento del cancer.
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
CA2486869C (en) 2002-05-31 2011-09-13 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
ES2381617T5 (es) 2002-08-14 2016-02-24 Macrogenics, Inc. Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20050239844A1 (en) * 2002-11-02 2005-10-27 Kyung-Lim Lee Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
CA2522562C (en) 2003-04-17 2013-09-03 Janssen Pharmaceutica N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
UA86962C2 (en) 2004-02-20 2009-06-10 Бёрингер Ингельхайм Интернациональ Гмбх Viral polymerase inhibitors
BRPI0510803A (pt) * 2004-05-12 2007-11-06 Proteotech Inc composto, composição farmacêutica, artigo de fabricação, métodos de tratar ou prevenir a formação, deposição, acúmulo ou persistência de fibrilas de amilóide e de fibrilas de sinucleìna, e de tratar, prevenir ou melhorar um ou mais sintomas de uma doença amilóide ou uma sinucleinopatia em um mamìfero, e, uso do composto
ES2362102T3 (es) 2004-06-30 2011-06-28 Janssen Pharmaceutica Nv Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer.
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
CA2627722A1 (en) † 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
NZ569327A (en) * 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
EP2505209A1 (en) 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-specific antibodies and methods of the use thereof
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AR077060A1 (es) 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
JP5690839B2 (ja) * 2009-12-04 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のベンゾイミダゾール阻害薬
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
SI2595965T1 (sl) * 2010-07-20 2016-09-30 Vestaron Corporation Insekticidni triazini in pirimidini
EP2632915B1 (en) 2010-10-29 2015-08-12 Boehringer Ingelheim International GmbH Benzimidazole inhibitors of leukotriene production
US8772304B2 (en) 2010-11-01 2014-07-08 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
US10889571B2 (en) 2018-09-18 2021-01-12 Terns, Inc. Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) * 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
ATE128030T1 (de) * 1990-08-02 1995-10-15 Hoffmann La Roche Antiallergische mischung.
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
JP3634861B2 (ja) * 1992-06-15 2005-03-30 セルテック リミテッド 選択的ホスホジエステラーゼｉｖ阻害剤としての三置換フェニル誘導体
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
RU2084451C1 (ru) * 1995-10-17 1997-07-20 Акционерное общество закрытого типа "Алмазный Центр" Способ получения 2-фенилбензимидазола
EP0973513A4 (en) * 1996-10-23 2003-03-19 Zymogenetics Inc COMPILATIONS AND METHOD FOR TREATING BONE DEFICIENCY
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
IL139828A0 (en) * 1998-05-22 2002-02-10 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
WO2002041219A1 (en) * 2000-11-15 2002-05-23 Manugistics Atlanta, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
CA2332985A1 (en) 1999-12-02
HUP0102128A3 (en) 2002-05-28
AU754943B2 (en) 2002-11-28
MXPA00011467A (es) 2002-10-17
BR9910641A (pt) 2001-10-02
CZ20004351A3 (cs) 2001-10-17
JP2002516274A (ja) 2002-06-04
HUP0102128A2 (hu) 2002-03-28
NO20005889L (no) 2001-01-22
CA2332989A1 (en) 1999-12-02
MXPA00011470A (es) 2002-10-17
ES2241285T3 (es) 2005-10-16
NZ508413A (en) 2003-08-29
NO20005888L (no) 2001-01-22
PL345560A1 (en) 2001-12-17
NO20005887D0 (no) 2000-11-21
UA67774C2 (uk) 2004-07-15
NZ508416A (en) 2004-01-30
CN1317965A (zh) 2001-10-17
ZA200007754B (en) 2001-08-16
IL139826A0 (en) 2002-02-10
EP1079830A1 (en) 2001-03-07
JP2002516276A (ja) 2002-06-04
WO1999061020A1 (en) 1999-12-02
IL139828A0 (en) 2002-02-10
WO1999061013A2 (en) 1999-12-02
ZA200007753B (en) 2001-07-18
UA67775C2 (uk) 2004-07-15
NO20005887L (no) 2001-01-19
EP1077700A1 (en) 2001-02-28
CN1721411A (zh) 2006-01-18
KR100591652B1 (ko) 2006-06-26
WO1999061019A1 (en) 1999-12-02
US6451829B2 (en) 2002-09-17
ZA200007752B (en) 2001-12-05
HUP0102550A3 (en) 2002-11-28
AU4312099A (en) 1999-12-13
BR9910642A (pt) 2001-10-09
CN1311679A (zh) 2001-09-05
EP1077700B1 (en) 2005-04-06
CN1219510C (zh) 2005-09-21
NO20005889D0 (no) 2000-11-21
CZ20004350A3 (cs) 2002-02-13
DE69924607D1 (de) 2005-05-12
PL345952A1 (en) 2002-01-14
HUP0101894A2 (hu) 2002-02-28
NO20005888D0 (no) 2000-11-21
ATE292465T1 (de) 2005-04-15
RU2236220C2 (ru) 2004-09-20
EP1077695A2 (en) 2001-02-28
US20020010343A1 (en) 2002-01-24
CA2332999A1 (en) 1999-12-02
CN1311675A (zh) 2001-09-05
BR9910640A (pt) 2001-10-30
RU2236221C2 (ru) 2004-09-20
HUP0102550A2 (hu) 2001-10-28
AU4197899A (en) 1999-12-13
AU754562B2 (en) 2002-11-21
WO1999061013A3 (en) 2000-04-06
IL139827A0 (en) 2002-02-10
DE69924607T2 (de) 2006-02-02
US6271390B1 (en) 2001-08-07
HUP0101894A3 (en) 2002-07-29
AU4094299A (en) 1999-12-13
JP2002516277A (ja) 2002-06-04
PL345219A1 (en) 2001-12-03
KR20010030179A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
MXPA00011422A (es) Derivados de bencimidazol como moduladores de ige.
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
DE69510940D1 (de) Pyrazolo und pyrrolopyridine
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE50201509D1 (de) Orthese zur Behandlung von Verletzungen des A-C-Gelenkes der Schulter
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
WO2002083700A3 (en) Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
FI972673A7 (fi) 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdiste itä
SE9901273D0 (sv) Novel compounds
EP1555020A3 (en) Benzimidazole derivatives as modulators IgE
ZA200503703B (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
LT2002131A (en) New use of fir oil for cosmetic
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
ATE275627T1 (de) Menschlicher site-1 protease-spezifischer promotor
TJ387B (en) The present invention relates to medicine and can be used for treatment of inflammatory process of aleather.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees